BIGG

Início > Guias GRADE > Resultado da busca

Resultados: 2

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). Last updated: 22 June 2022

England. National Institute for Health and Care Excellence.
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VI...
Vacinas contra COVID-19/efeitos adversos, Púrpura Trombocitopênica Idiopática/complicações, Trombose/complicações, SARS-CoV-2/efeitos dos fármacos, Ad26COVS1/efeitos adversos, ChAdOx1 nCoV-19/efeitos adversos, Vacina BNT162/efeitos adversos
Texto completo

Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices: United States, December 2021

Oliver, Sara E; Wallace, Megan; See, Isaac; Mbaeyi, Sarah; Godfrey, Monica; Hadler, Stephen C; Jatlaoui, Tara C; Twentyman, Evelyn; Hughes, Michelle M; Rao, Agam K; Fiore, Anthony; Su, John R; Broder, Karen R; Shimabukuro, Tom; Lale, Allison; Shay, David K; Markowitz, Lauri E; Wharton, Melinda; Bell, Beth P; Brooks, Oliver; McNally, Veronica; Lee, Grace M; Talbot, H. Keipp; Daley, Matthew F.
MMWR recomm. rep; 71 (3), 2022
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
Trombose/complicações, Ad26COVS1/efeitos adversos, Programas de Imunização/normas, COVID-19/prevenção & controle, Síndrome de Guillain-Barré/complicações
Texto completo